Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 5

Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release

Authors Werz M

Published 10 October 2008 Volume 2008:4(5) Pages 1035—1046

DOI https://doi.org/10.2147/TCRM.S3343

Review by Single-blind

Peer reviewer comments 3

Mary Ann Werz

Department of Neurology, Case Medical Center, Cleveland, Ohio USA

Abstract: The goal in managing patients with epilepsy is complete seizure freedom. Pharmacotherapeutic management of epilepsy is complicated by multiple syndromes, interindividual differences in drug sensitivities, inter-individual differences in drug disposition, and drug interactions. Most anti-epileptic drugs (AEDs) have a therapeutic window with only a 2- to 3-fold concentration range. Extended release formulations offer advantages over their immediate release counter parts with less fluctuation in the serum concentration vs time curve and improved compliance. However, missed doses are more likely to result in prolonged “subtherapeutic serum concentrations”. Best clinical outcome may sometimes require twice daily dosing of extended release formulations even though approved for once daily dosing, as this optimally balances pharmacokinetics against compliance. Lamotrigine (LTG) is a broad spectrum AED with efficacy in partial and generalized epilepsy syndromes and good tolerability. Its metabolism is affected by co-medications which may be inducing, neutral or inhibiting of hepatic glucuronidation. Furthermore, though the average half-life in monotherapy is about 24 hours, there is a large inter-individual variation that may, including the extremes, approach a range of 10-fold. LTG-XR is expected to decrease fluctuation of serum concentration in the presence of hepatic inducing or neutral drugs. However, optimal clinical benefit in some patients may require twice daily dosing when metabolism is rapid.

Keywords: lamotrigine, antiepileptic drugs, extended release, epilepsy, pharmacokinetics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice

Pan Y, Jia T, Zhang Y, Zhang K, Zhang R, Li J, Wang L

International Journal of Nanomedicine 2012, 7:5957-5967

Published Date: 3 December 2012

Choroidal excavation with polypoidal choroidal vasculopathy: a case report

Kobayashi W, Abe T, Tamai H, Nakazawa T

Clinical Ophthalmology 2012, 6:1373-1376

Published Date: 27 August 2012

Citing first publication

Netland PA

Clinical Ophthalmology 2012, 6:605-606

Published Date: 20 April 2012

Pharmacological management of acute bronchiolitis

Melvin Wright, Charles J Mullett, Giovanni Piedimonte

Therapeutics and Clinical Risk Management 2008, 4:895-903

Published Date: 10 October 2008

Corrigendum

Dove Medical Press Editorial

Clinical Interventions in Aging 2008, 3:397-397

Published Date: 6 June 2008

Therapeutical approach to plasma homocysteine and cardiovascular risk reduction

Marcello Ciaccio, Giulia Bivona, Chiara Bellia

Therapeutics and Clinical Risk Management 2008, 4:219-224

Published Date: 8 February 2008